U.S. FDA approves Gilead's all-oral hepatitis C drug
October 10, 2014 at 13:58 PM EDT
Oct 10 (Reuters) - U.S. regulators on Friday approved Gilead Sciences Inc's all-oral hepatitis C drug, clearing the way for the company to increase its revenue from sales of treatments for the liver-destroying viral infection.
